REPL Investor Notice: Levi & Korsinsky Investigates Replimune Group, Inc. for Securities Law Violations

New York, New York--(Newsfile Corp. - July 23, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Replimune Group, Inc. ("Replimune Group, Inc.") (NASDAQ: REPL) concerning possible violations of federal securities laws.

On July 22, 2025, Replimune announced that it received a Complete Response Letter from the FDA rejecting its Biologics License Application for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. In the CRL, the FDA indicated that "the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness."

Following this news, REPL's stock price fell over 78% to open at $2.70 per share on July 22, 2025.
To obtain additional information, go to:

https://zlk.com/pslra-1/replimune-group-inc-lawsuit-submission-form?prid=157760&wire=5&utm_campaign=63

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212)363-7500.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/259773